07.05.2013 18:20 Uhr, Quelle: Presseportal

Pivotal Therapeutics VASCAZEN®-REVEAL Trial Meets Primary and Secondary Endpoints - VASCAZEN® Shows 121% Correction of an Omega-3 Deficiency (p< 0.0001) with a Concomittant 48% Reduction in Triglycerides (p<0.0005)

Pivotal Therapeutics Inc: Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, presented positive, statistically

Weiterlesen bei Presseportal